Introduction
and peripheral lymphoid organs, they can also infiltrate tumour tissue and constitute approximately 5% of the total cells within the mass [13] .
Multiple [14] [15] [16] . [17] [18] [19] .
The importance of IRF-8 in regulating normal myelopoiesis has been clearly illustrated in IRF-8 null mice

IRF-8-deficiency alters normal haematopoiesis, and leads to a marked accumulation of macrophages, neutrophils and CD11b
ϩ Gr-1 ϩ cells in the spleen, lymph nodes, peripheral blood and bone marrow [17] [18] [19] .
Additionally, IRF-8-deficient macrophages and neutrophils exhibit heightened levels of apoptotic resistance [20] . Ultimately, these mice develop a chronic myelogenous leukaemia-like syndrome [17] ,
revealing that IRF-8 plays an integral role in the regulation of cell death and the pathogenesis of certain haematological malignancies. These observations also raise the notion that the production or accumulation of CD11b
ϩ [21] [22] [23] [24] , henceforth termed MTAG mice [25, 26] . These mice develop tissue-specific mammary gland carcinoma, which eventually metastasizes to the lungs. Tumour progression in MTAG mice has been shown to mimic human breast cancer pathology at morphological (disease stage), molecular and immunological levels [25] [26] [27] [28] . Moreover, we recently demonstrated that autochthonous primary tumour growth in MTAG mice was accompanied by a significant accumulation of splenic CD11b ϩ Gr-1 ϩ cells [26] . This model has also been used to study the role of tumour-associated macrophages in tumour progression [29] . 
Gr-1 ϩ MDSC in tumour-bearing hosts arise, at least in part, as a consequence of a novel mechanism of tumour-induced IRF-8 down-regulation. To test this hypothesis, we made use of both implantable (4T1) and transgenic (MMTV-PyMT) mouse models of mammary carcinoma. The 4T1 tumour cell line is a well characterized model, reflecting a spontaneously arising neoplasm in BALB/c mice
. When implanted orthotopically into a mammary gland of syngeneic mice, 4T1 exhibits progressive tumour growth that is accompanied by spontaneous metastasis to the lymph nodes, lung, liver, bone marrow and brain, as well as a rapid and robust accumulation of MDSC that are readily detectable in peripheral lymphoid tissues. The second model involved the use of transgenic (Tg) mice expressing the polyomavirus middle T antigen (PyMT) under the transcriptional control of the MMTV promoter
In both the 4T1 and MTAG models, we showed that tumourinduced CD11b
RT-PCR and PCR analyses
For RT-PCR, total RNA was isolated from CD11b [26] . 3A and B) . IFN-␥/LPS were used to optimally up-regulate IRF-8 expression, as previously described [18, 33] . In some experiments, cell-free supernatants were recovered for cytokine analysis ( Fig. 3C and D 
Results
Accumulation of CD11b
IRF-8 is down-regulated in tumour-induced CD11b
see D). (Lower gel of A) In a separate experiment, IRF-8 expression levels were determined, as described above, from a control group ('B') and five individual tumour-bearing mice ('6-10'). Control CD11b
Gr-1 ϩ cells purified from bone marrow of control (a; d-h) and 4T1 tumour-bearing CB6F1/J mice (b, c; i-l), as in (A). The results are summarized from two independent experiments shown as, 'a-c' and 'd-l'. Samples shown as 'd-l' represent data from individual mice, whereas samples shown as 'a, b and c' represent data from pools of five, two and two mice, respectively. The relative levels of IRF-8 shown in (A) and (B) were quantified by analysis of the PCR band intensities, as described in the 'Materials and methods'. The first lane of each of the four gels was arbitrarily set at a relative intensity of 1. (C and D) Tumour-induced CD11b
ϩ
Gr-1 ϩ cells also displayed an altered IL-12/IL-10 profile. CD11b
ϩ (Fig. 4) . [34, 35] , compared with control cells (P ϭ 0.009; Fig. 2D ), which verified that these preparations were functionally intact, but biologically altered.
Gr-1 ϩ cells of the same control ('C') and 4T1 tumour-bearing groups shown in (A) were also analysed for production of IL-12 (IL-12p70) and IL-10 following stimulation with IFN-␥ and LPS overnight. Cytokines were undetectable in the absence of stimulation (not shown). Data represent the mean Ϯ S.E.M. of triplicate determinations for cytokine concentration from each preparation. Experiments were repeated in BALB/c mice with similar results. in constitutive IRF-8 expression levels in tumour-induced
The analysis of IRF-8 expression was extended to CD11b
cells purified from the bone marrow of tumour-bearing mice (Fig. 3B, mice b and c; i-l) were found to be greatly reduced compared to controls (Fig. 3B, mice a; d-h). In all cases, IRF-8 expression levels of the controls were similar to each other (Fig. 3B, mice a, d-h) and consistently higher than those observed in samples from tumour-bearing mice (Fig. 3B upper and lower panels, a versus b or c; d-h versus i-l). Therefore, in this 4T1 model, the data indicated that IRF-8 expression within tumour-induced CD11b
Transgenic expression of IRF-8 reduces the accumulation of tumour-induced CD11b
ϩ and/or IL-1 [4, 5, 8, 22, 32, 36, 37] 
Gr-1 ϩ cells
Thus far, these data indicate an inverse correlation between IRF-8 levels and the emergence of tumour-induced CD11b
), was assessed, indicated as pairs (A), (B) (upper gel) or (C) (lower gel). (Lower right panel) The relative levels of IRF-8 shown for mouse pairs (A)-(C) were then quantified by analysis of the PCR band intensities, as in Fig. 2. We divided (or standardized) each individual ratio (IRF-8/␤-actin) by the mean ratio of the Tg-group (without in vitro treatment) to yield a relative ratio. The graph depicts the relative ratio for each of the twelve observations (n ϭ 3 corresponding to groups A, B and C/in vitro treatment). The horizontal lines indicate the means of the standardized values. studies, which revealed no overt differences in the frequencies and absolute numbers of major splenic leucocyte subsets (e.g. T-cell subsets, B cells and myeloid populations) from IRF-8 transgenic versus wild-type mice (data not shown). To evaluate the in vivo effects of IRF-8 transgene expression on tumour growth and CD11b
